Filing summary
Entity and period: The supplied filing is AntriaBio, Inc.’s Form 10-Q for the quarter ended March 31, 2015, filed May 15, 2015. This does not match the request metadata identifying Rezolute, Inc. and 2014 Q3; verify that this is the intended filing. The company describes itself as a preclinical biopharmaceutical company.
Financial results and position
The company had no revenue. Figures below are in U.S. dollars.
| Metric | Three months ended March 31, 2015 | Three months ended March 31, 2014 | Nine months ended March 31, 2015 | Nine months ended March 31, 2014 |
|---|---|---|---|---|
| Research and development expense | $1.291 million | $2,246 | $2.970 million | $2,246 |
| General and administrative expense | $1.009 million | $1.593 million | $4.635 million | $2.944 million |
| Operating loss | $2.300 million | $1.595 million | $7.604 million | $2.946 million |
| Net loss | $3.173 million | $5.087 million | $8.323 million | $7.725 million |
| Net loss per share | $0.14 | $0.76 | $0.42 | $1.16 |
- Cash and liquidity: At March 31, 2015, cash was $8.225 million and restricted cash was $450,055. Current assets were $8.942 million and current liabilities were $1.798 million. Working capital was $7.144 million.
- Cash flows: Nine-month operating cash use was $5.116 million; investing cash use was $1.380 million; financing cash provided was $8.786 million. Cash increased $2.290 million from $5.935 million.
- Debt and liabilities: Total liabilities were $2.352 million, including $60,000 in matured convertible notes payable, due on demand and accruing interest at 8%. Lease payable totaled $139,858. The filing reports no other material debt facility.
- Equity: Stockholders’ equity was $9.704 million, with an accumulated deficit of $26.070 million. Common shares outstanding were 23.536 million at quarter-end and 24.338 million as of May 15, 2015.
- Margins: Revenue and gross profit were absent, so operating and gross margins are not meaningful.
Changes versus prior comparable periods
- Nine-month net loss widened by about $598,000 year over year, while the quarterly net loss narrowed by about $1.914 million. The quarterly comparison benefited from much lower interest expense: $2,086 versus $3.441 million, largely reflecting prior-year amortization of debt discounts and beneficial conversion features.
- Nine-month operating expenses increased to $7.604 million from $2.946 million. R&D spending rose sharply as significant development activities began; G&A increased, including from higher stock-based compensation, staffing, and investor-relations costs.
- Cash rose from $5.935 million at June 30, 2014 to $8.225 million at March 31, 2015, primarily supported by equity financing. Fixed assets increased to $2.303 million from $338,000, reflecting facility buildout and equipment-related investment.
- Shares issued and outstanding increased to 23.536 million from 18.092 million at June 30, 2014. The company also reported 17.998 million warrants outstanding and 8.662 million options outstanding at quarter-end.
Outlook, risks, and notable items
- Development plans: 2015 objectives included completing a cGMP manufacturing suite, producing AB101 material, completing toxicology studies, filing an IND, beginning a first clinical study in Q4 2015, and announcing another pipeline candidate. The company said it had begun animal studies and anticipated the suite’s completion by August 2015; construction, equipment, manufacturing, toxicology, or regulatory delays could push back clinical plans.
- Funding and going concern: Management stated cash and expected operating cash flows would not sustain operations for more than one year and that additional financing was needed. The filing says substantial doubt exists about the company’s ability to continue as a going concern. Management estimated average monthly general operating expenses of about $500,000 and forecast cash sufficiency well into the first half of calendar 2016, but also said additional capital was needed to fund planned operations and the clinical study.
- Planned spending: Management estimated at least $2.5 million for the manufacturing suite, $1.5–2 million for additional equipment, and about $4 million for the first AB101 clinical study.
- Financing and dilution: The company reported approximately $22 million raised toward a $25–30 million target in calendar 2014 and early 2015. Additional equity financing could dilute shareholders; financing availability and terms were uncertain. A private-placement final close on April 6, 2015 generated a further $1.4 million gross proceeds.
- Unusual/noncash items: Derivative losses were $871,447 in the quarter and $717,733 for the nine months, associated with warrant fair-value accounting. Stock-based compensation was $1.864 million for the nine months. A $132,339 related-party payable was forgiven and written off.
- Commitments and litigation: The office, laboratory, and clean-room lease runs 72 months; minimum rental commitments were $1.928 million at quarter-end. The company reported no pending or threatened lawsuits expected to have a material operational effect.
- Controls: Management concluded disclosure controls were ineffective as of March 31, 2015 because of a material weakness involving inadequate segregation of duties and the need for a stronger internal-control environment, attributed to the small staff.
Important facts for investors to verify
- Confirm the filing identity and period: the document is for AntriaBio, Inc., quarter ended March 31, 2015, not Rezolute, Inc. 2014 Q3.
- Reconcile the MD&A statement of $8.7 million cash on hand with the balance sheet’s $8.225 million cash plus $450,055 restricted cash.
- Assess runway and the timing, amount, and terms of additional financing against management’s going-concern warning and planned development costs.
- Track completion and validation of the cGMP suite, AB101 manufacturing and toxicology results, IND acceptance, and clinical-study timing.
- Review warrant valuation and potential dilution, the matured $60,000 convertible notes, and remediation of the disclosed material weakness.